JAGSONPAL Pharmaceuticals Ltd. reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2016. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 389.201 million against INR 388.486 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 40.029 million against INR 9.33 million a year ago. Profit from ordinary activities before tax was INR 23.588 million against loss from ordinary activities before tax INR 0.681 million a year ago. Net profit from ordinary activities after tax was INR 20.011 million against INR 0.679 million a year ago. Basic and diluted earnings per share (after extraordinary items) were INR 0.76 against INR 0.03 a year ago. For the year, the company reported net sales/income from operations (net of excise duty) of INR 1,440.805 million against INR 1,381.509 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 93.085 million against INR 60.192 million a year ago. Profit from ordinary activities before tax was INR 40.752 million against INR 16.717 million a year ago. Net profit from ordinary activities after was INR 32.542 million against INR 11.711 million a year ago. Basic and diluted earnings per share (after extraordinary items) were INR 1.24 against INR 0.45 a year ago.